Insulet (NASDAQ:PODD)‘s stock had its “outperform” rating reiterated by stock analysts at Cowen in a research report issued to clients and investors on Thursday. They currently have a $90.00 price objective on the medical instruments supplier’s stock, up from their prior price objective of $80.00. Cowen’s price target would suggest a potential upside of 11.86% from the stock’s current price.
Several other brokerages have also commented on PODD. Barclays lifted their price objective on shares of Insulet from $70.00 to $75.00 and gave the stock an “overweight” rating in a research report on Monday, November 20th. Morgan Stanley lifted their price objective on shares of Insulet from $55.00 to $63.00 and gave the stock an “equal weight” rating in a research report on Friday, November 3rd. BidaskClub raised shares of Insulet from a “sell” rating to a “hold” rating in a research report on Friday, January 26th. Zacks Investment Research lowered shares of Insulet from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Finally, Oppenheimer set a $82.00 price objective on shares of Insulet and gave the stock a “hold” rating in a research report on Thursday. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $69.31.
Insulet (NASDAQ PODD) traded up $2.72 during trading on Thursday, reaching $80.46. 1,131,700 shares of the company traded hands, compared to its average volume of 535,240. Insulet has a 1-year low of $38.43 and a 1-year high of $83.56. The stock has a market capitalization of $4,523.52, a PE ratio of -174.91 and a beta of 1.59. The company has a current ratio of 4.88, a quick ratio of 4.42 and a debt-to-equity ratio of 4.65.
A number of large investors have recently modified their holdings of PODD. Cerebellum GP LLC purchased a new position in Insulet during the fourth quarter valued at approximately $122,000. Equitec Specialists LLC purchased a new position in Insulet during the fourth quarter valued at approximately $145,000. James Hambro & Partners purchased a new position in Insulet during the fourth quarter valued at approximately $165,000. C M Bidwell & Associates Ltd. purchased a new position in Insulet during the fourth quarter valued at approximately $188,000. Finally, Diversified Trust Co purchased a new position in Insulet during the fourth quarter valued at approximately $218,000.
COPYRIGHT VIOLATION WARNING: “Insulet (PODD) Given “Outperform” Rating at Cowen” was first posted by Markets Daily and is the sole property of of Markets Daily. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://www.themarketsdaily.com/2018/02/23/insulet-podd-price-target-raised-to-90-00-at-cowen.html.
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.